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ABSTRACT
DNA methylation is an epigenetic modification
of the mammalian genome that occurs predomin-
antly at cytosine residues of the CpG dinucleotide.
Following formaldehyde activation, pixantrone
alkylates DNA and particularly favours the CpG
motif. Aberrations in CpG methylation patterns
are a feature of most cancer types, a characteristic
that may determine their susceptibility to specific
drug treatments. Given their common target, DNA
methylation may modulate the DNA damage
induced by formaldehyde-activated pixantrone.
In vitro transcription, mass spectrometry and
oligonucleotide band shift assays were utilized to
establish that pixantrone–DNA adduct formation
was consistently enhanced 2–5-fold at discrete
methylated CpG doublets. The methylation-
mediated enhancement was exquisitely sensitive
to the position of the methyl substituent since
methylation at neighboring cytosine residues
failed to confer an increase in pixantrone–DNA
alkylation. Covalent modification of DNA by
formaldehyde-activated doxorubicin, but not
cisplatin, was augmented by neighbouring CpG
methylation, indicating that modulation of binding
by CpG methylation is not a general feature of
all alkylators. HCT116 colon cancer cells vastly
deficient in CpG methylation were 12- and 10-fold
more resistant to pixantrone and doxorubicin
relative to the wild-type line, suggesting that these
drugs may selectively recognize the aberrant CpG
methylation profiles characteristic of most tumour
types.
INTRODUCTION
Pixantrone is a novel aza-anthracenedione that was orig-
inally developed to improve the therapeutic proﬁle of
mitoxantrone, a DNA-interactive agent currently used in
the clinical management of a range of haematological
malignancies and solid tumours (1). Like mitoxantrone,
pixantrone interacts with DNA via intercalation (2) and
stimulates topoisomerase II-mediated DNA cleavage (3,4)
presumably by stabilizing the cleavable complex (5).
Despite the drug’s ability to stimulate DNA cleavage via
topoisomerase II impairment, this form of DNA damage
does not directly correlate with drug cytotoxicity (3–5),
suggesting that pixantrone may operate by a distinct,
currently undeﬁned mechanism of cell kill. A novel form
of pixantrone–DNA interaction has recently emerged
in which the drug can be extrinsically activated by form-
aldehyde to form covalent drug–DNA adducts (6).
Formaldehyde-activated pixantrone exhibits considerable
discrimination in alkylating DNA selectively at CpG and
CpA dinucleotides via the terminal primary amino group
of a single drug side-chain (7).
In addition to being a favoured target of formaldehyde-
activated pixantrone, the CpG dinucleotide is unique in
other respects. Globally, the mammalian genome
comprises  50 million CpG doublets (8) and therefore
occurs well below its expected statistical frequency
(8–11). The spatial distribution of CpG dinucleotides
across the genome is uneven and non-random (10) and
includes vast stretches of genomic DNA deﬁcient in this
speciﬁc doublet (8,10,12). These extensive stretches are
punctuated by relatively small clusters of CpG sequences,
 1kbin length, termed CpG islands (8,10–12). CpG
islands are closely associated with regulatory promoter
regions of many mammalian genes (9–13).
Although most CpG sequences are methylated in the
mammalian genome, CpG islands harbour over 50% of
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remain unmethylated throughout development in
most tissues (10,11,14). Cytosine methylation typically
occurs following DNA replication, predominantly by
the maintenance methyltransferase DNMT1 (8,10,12).
DNMT1 is responsible for the faithful transmission of
CpG methylation patterns between cell generations by
the post-replicative re-establishment of hemi-methylated
CpG doublets to a fully methylated status (8,12,14) and
CpG methylation patterns are actively maintained follow-
ing each cell division.
DNA methylation assumes an important role in
numerous physiological events that include embryonic
development, genomic imprinting and X-inactivation
by aﬀording the cell an additional element of information
storage without aﬀecting the primary nucleotide sequence
(8,14). Modiﬁcation of the genome by methylation, par-
ticularly those CpG islands aﬃliated with imprinted
genes and X chromosome inactivated genes, enables the
stable transcriptional suppression of the associated gene
(10,12,14). Recently, it has been established that numerous
cancer-related genes can also be inactivated following the
aberrant methylation of CpG islands in their promoter
regions and this can have signiﬁcant implications for
the development of cancer (10–12,14). Cancer-speciﬁc
methylation of CpG islands has been established in a
range of tumour suppressor genes, DNA repair genes
and genes that suppress angiogenesis, tumour invasion
and metastasis (11,12,14).
An expanding list of genes that are susceptible to inac-
tivation by aberrant hypermethylation has enabled
investigators to analyse the patterns of silenced genes
among diﬀerent cancer types (15,16). Each tumour type
has a distinctive proﬁle of CpG island hypermethylation
(15–19), which may facilitate the construction of a
powerful set of biomarkers for tumour classiﬁcation (19)
and diagnostics (8,16). A prominent example is the
hypermethylation-mediated inactivation of BRCA1, a
DNA double strand break repair gene, which is frequently
detected in breast and ovarian tumours, but not in other
cancer types (16). Such a strong emphasis on cancer-
speciﬁc, genome-wide CpG methylation proﬁling in
recent times has seen the term cancer ‘methylome’
become fashionable (17).
DNA methylation proﬁling of cancers may also be used
as a predictor for the susceptibility of a cancer to a speciﬁc
drug treatment and this may have signiﬁcant implications
for drugs that target the CpG doublet (20,21). It is con-
ceivable that CpG speciﬁc drugs, such as activated
pixantrone, may recognize the aberrant methylation
proﬁles that are characteristic of cancer cells. Perhaps
more importantly, the methylation status of CpG
dinucleotides may modulate the biological response to
the drug. At a global level, DNA fragments methylated
by SssI methylase are highly susceptible to adduct-induced
duplex stabilization by formaldehyde-activated pixan-
trone (7). However, the eﬀect of more localized CpG
methylation on pixantrone–DNA interactions, namely at
individual CpG doublets, has not been thoroughly
characterized. Given the localized hypermethylation of
CpG islands and the associated silencing of many
cancer-related genes within neoplastic cells, the modula-
tion of pixantrone–DNA interactions by methylation at
localized CpG sequences was the primary focus of the
present study.
MATERIALS AND METHODS
Materials
Pixantrone was kindly supplied by Cell Therapeutics
Europe (CTE) (Bresso, Italy), while doxorubicin was
a gift from Pﬁzer (Milan, Italy). Cisplatin and
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (MTT) were from Sigma Chemical Co, while
formaldehyde was purchased from BDH. The DNA mod-
ifying enzymes HpaII methylase, HhaI methylase and
MspI methylase were purchased from New England
Biolabs. The restriction endonucleases HpaII, HhaI
and MspI were obtained from Promega. All remaining
chemicals and reagents were of analytical grade.
Distilled water passed through a four-stage Milli-Q puri-
ﬁcation system (Millipore) was used to prepare all
solutions.
Drugs
Stock solutions of pixantrone and doxorubicin were
prepared by dissolving each in Milli-Q water to a ﬁnal
approximate concentration of 1–2mM. The precise
concentrations of each drug stock were determined
spectrophotometrically using the extinction coeﬃcients
"1%
1cm =296 at 641nm and e=11500M
 1cm
 1 at
480nm for pixantrone and doxorubicin, respectively.
Each drug stock was subsequently stored at  20 C.
An accurately prepared mass of cisplatin was dissolved
in 0.9% sodium chloride solution to generate a stock con-
centration of 1.58mM. Cisplatin and formaldehyde
solutions were prepared freshly on the day of each
experiment.
DNA source
Plasmid pCC1 and the 512bp fragment containing the
lac UV5 promoter derived from the plasmid were
prepared as described previously (6,7). The sequences of
both unmethylated and methylated oligonucleotides
(obtained from Geneworks) were: BE1, 50-TTATTTCCG
GCGCCTTATTT-30; BE2, 50-AAATAAGGCGCCGGA
AATAA-30; BE6, 50-TTATTTCC
MeGGC
MeGCCTTAT
TT-30; and BE7, 50-AAATAAGGC
MeGCC
MeGGAAAT
AA-30.C
Me represents the modiﬁed base 5-methylcytosine.
The extinction coeﬃcients for each oligonucleotide were
determined using a formula provided by Wallace and
Miyada (22).
Puriﬁcation, labelling and annealing of oligonucleotides
Duplex oligonucleotides were prepared as described in
Evison et al. (7). This protocol enabled the genera-
tion of four distinct duplexes including unmethylated
dsBE12, hemi-methylated dsBE17 and dsBE26 and fully
methylated dsBE67.
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The 512bp fragment was incubated with HpaII methylase
and 80mM S-adenosyl-methionine at 37 C overnight. This
reaction enabled the methylation of the internal cytosine
residue of ﬁve independent 50-CCGG-30 sequences that
occur within the 512bp fragment. The methylation
status of the fragment was conﬁrmed by challenging the
DNA with HpaII, an endonuclease that speciﬁcally
cleaves DNA at unmethylated CCGG sites. Products of
the restriction digest were separated and visualized
electrophoretically, and in each case the 512bp fragment
remained intact, suggesting that the DNA was fully
methylated.
In separate reactions, the 512bp fragment was speciﬁ-
cally methylated at either the external cytosine of the ﬁve
CCGG sites or at the internal cytosine of four independent
50-GCGC-30 sequences using MspI methylase and HhaI
methylase, respectively. Methylation of the fragment was
conﬁrmed by establishing that the modiﬁed sequences
were resistant to cleavage by the appropriate restriction
endonuclease. Both native (unmethylated) and methylated
512bp fragments were used as templates for all subse-
quent transcription studies.
Drug reaction conditions
Generally, covalent drug–DNA adducts were generated in
a reaction mixture consisting of the following: either
native or methylated DNA was reacted with pixantrone
or doxorubicin (together with formaldehyde) in phosphate
buﬀered saline (PBS) (pH7.0) at 37 C. The composition
and conditions of each reaction were highly assay-
dependent and are speciﬁed in the appropriate ﬁgure
legend.
In vitro transcription assay
Drug-reacted DNA samples were typically processed and
subjected to in vitro transcription assays as originally
described (7). In vitro transcription samples were pro-
cessed and electrophoresed through 12% denaturing
polyacrylamide gels. Gels were subsequently ﬁxed in
10% glacial acetic acid/10% methanol, dried, analysed
by phosphorimaging and quantitated using ImageQuant
software (Molecular Dynamics, CA).
Oligonucleotide band shift assay
Following reaction with pixantrone and formaldehyde,
[
32P]-end labelled oligonucleotide samples were subjected
to a gel shift assay as previously described (7). DNA
adduct stability studies using the gel shift assay were per-
formed in a similar manner, however two modiﬁcations to
the procedure were introduced. Firstly, following the com-
pletion of each reaction, samples were passed through a
Micro Bio-Spin 6 chromatography column to remove
unreacted drug from the mix. Secondly, the puriﬁed
samples were subsequently incubated at 37 C for deﬁned
time periods up to 3h. Samples were then subjected to
19% denaturing PAGE overnight at 600V at room tem-
perature. Gels were subsequently ﬁxed as described earlier,
exposed to a Phosphor screen for 2h and then analysed
and quantitated as described previously.
Mass spectrometry studies
Oligonucleotide duplexes dsBE12 or dsBE67 were initially
reacted with formaldehyde and pixantrone to yield a
covalent pixantrone–DNA complex, which was subse-
quently puriﬁed by electrophoresis followed by electro-
elution. Initially, samples were directly loaded onto a
cooled pre-electrophoresed 19% denaturing polyacry-
lamide gel (18 23cm) and then subjected to electro-
phoresis at 4 C overnight at 300V. Electrophoretic
resolution of the covalent pixantrone–DNA complex
yielded a blue band that was clearly visible to the naked
eye. The blue band was subsequently excised from the gel
with a clean scalpel and the pixantrone–DNA complex
electroeluted from the gel slice using the Elutrap
apparatus at 120V for 3h at 4 C. The puriﬁed covalent
drug–DNA complex was subsequently subjected to centri-
fugation at 14 C for 2h at 6500 g using a Centricon
Centrifugal Filter Unit (MWCO 3kDa) and then
desalted four times into 10mM ammonium acetate
by gel ﬁltration (Micro Bio-Spin 6 chromatogra-
phy column). Mass spectrometric analysis of the drug–
DNA complex was then carried out as described
earlier (7).
Cell culture and growth inhibition assays
The human colorectal cancer cell line HCT116 and an
isogenic derivative HCT116DKO (clone 1; deﬁcient in
DNMT1 and DNMT3b) were provided by Prof. Bert
Vogelstein (John Hopkins University, MD, USA). Both
cell lines were maintained in RPMI 1640 medium
(Invitrogen) supplemented with 10% FCS (Trace
Scientiﬁc) and grown in a humidiﬁed incubator at 37 C
with 5% CO2.
Growth inhibition was evaluated using an MTT assay.
Cells were initially seeded at 3000 or 10000 cells per well
(HCT116 and HCT116DKO, respectively) into 96-well
plates and allowed to attach for 24h. Cells were treated
with drug and incubated for a further 72h. MTT
was dissolved in PBS, sterile ﬁltered and diluted to
1mg/mlin serum-free culture medium. The MTT mix
was added to cells (ﬁnal concentration 0.33mg/ml) and
incubated for a further 2.5h. Media was subsequently
removed by aspiration and the insoluble MTT crystals
dissolved in DMSO. Following reconstitution, the
absorbance of MTT was measured at 570nm. Drug
concentrations inducing a level of 50% growth inhibition
(IC50) were determined using Microcal Origin software.
RESULTS
One of the most signiﬁcant changes in the methylation
pattern of a cancer cell is the local hypermethylation of
CpG islands of many cancer-related genes (11,12,14). The
in vitro transcription assay is an ideal system for
investigating the eﬀect of local CpG methylation on
novel drug–DNA interactions given its ability to probe
individual drug binding sites with exquisite sensitivity.
Nucleic Acids Research, 2009,Vol.37, No. 19 6357Consequently, in vitro transcription was initially used to
examine the inﬂuence of CpG methylation on formal-
dehyde-activated pixantrone-induced DNA damage at
discrete, localized CpG dinucleotides.
Localized CCm
5GG methylation by HpaII
methylase enhances the generation of pixantrone–
DNA adducts
Prior to transcription, a native, unmethylated 512bp
fragment containing the lac UV5 promoter was pre-
reacted with 2mM formaldehyde and increasing
concentrations of pixantrone (0–10mM). Each sample
was subsequently subjected to transcription initiation by
the addition of Escherichia coli RNA polymerase and the
extension of each initiated transcript permitted by the
addition of high concentrations of all four nucleotides.
In the absence of pixantrone (lane 0, Figure 1A), the
enzyme transcribes eﬃciently through the template to
generate a full length RNA transcript 379 bases long.
Importantly, no blockages are evident in this control
(lane 0, Figure 1A), which suggests that formaldehyde
alone does not induce transcriptional blockages. With
increasing concentrations of pixantrone, RNA polymerase
becomes increasingly blocked at speciﬁc sites (lanes
0.25–10, Figure 1A). The pattern of transcriptional
blockages depicted in Figure 1A is consistent with the
CpG and CpA selectivity of formaldehyde-activated
pixantrone DNA adducts reported previously (7).
Multiple reactions containing 2mM formaldehyde and
pixantrone (0–10mM) were run in parallel, however the
native, unmethylated 512bp fragment was substituted
for an identical fragment methylated by HpaII methylase,
an enzyme that transfers a methyl group to the internal
cytosine residue of its target sequence CCGG (denoted
CCm
5GG). Following transcription, HpaII-methylated
DNA templates yielded a proﬁle of drug-induced block-
ages (Figure 1B) identical in pattern to the transcriptional
footprint induced using the unmethylated DNA template
(Figure 1A). Although the pattern of blockages remains
the same, there is a clear increase in the intensity of drug-
induced blockages speciﬁcally at CCm
5GG sites originally
methylated by HpaII methylase (indicated by sites X, Y
and Z at the right of Figure 1B). The pixantrone-induced
blockages at sites X, Y and Z were quantitated as a
fraction of all transcripts in each lane and are represented
as a function of pixantrone concentration in Figure 1C–E.
These graphs show that pixantrone–DNA adduct forma-
tion is enhanced 2–3-fold at each of the three CCm
5GG
sites relative to the corresponding unmethylated CCGG
sequences (Figure 1C–E). As an internal control, the
fraction of transcriptional blockages at an unmethylated
CpG site was quantitated (indicated by CS at the right
of Figure 1B, and shown in Figure 1F) and reveals that
there was no signiﬁcant diﬀerence in the generation of
pixantrone–DNA adducts at unmethylated sites on
either the native or methylated DNA template. Such a
control indicates that the enhancement of pixantrone–
DNA adducts occurs speciﬁcally at localized CCm
5GG
sites and is not a general, non-speciﬁc event.
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Figure 1. Drug-induced transcriptional blockages are enhanced at
discrete HpaII-methylated sequences. (A) A 512bp DNA fragment
(25mMbp) containing the lac UV5 promoter was reacted with
pixantrone (0–10mM as indicated) and 2mM formaldehyde for 4h.
Samples were subsequently ethanol precipitated, resuspended in tran-
scription buﬀer and then subjected to transcription. Following initia-
tion from the lac UV5 promoter, the transcription complex was
elongated for 5min and then terminated. Lanes I and E are controls
representing an initiated complex that has not been elongated and
extension of this complex to generate the full length transcript, respec-
tively. Lanes A and C are sequencing lanes which were obtained using
30-O-methoxy-ATP or 30-O-methoxy-CTP during elongation, respec-
tively. The length of selected transcripts is indicated at the left of the
phosphorimage. (B) The native 512bp fragment in (A) was substituted
for an identical fragment speciﬁcally methylated by HpaII methylase at
the internal cytosine of each CCGG recognition sequence. The
methylated fragment was subsequently reacted with drug and subjected
to transcription as described in (A). CCGG sites are indicated by X, Y
and Z at the right of the phosphorimage, while CS denotes an
unmethylated CpG site used as a control. The percentage of drug-
induced blockages at native (solid squares) and methylated (open
squares) sites X, Y and Z were quantitated as a fraction of each
entire lane and are represented as a function of pixantrone concentra-
tion in (C), (D) and (E), respectively. (F) The percentage transcriptional
blockage of the control site CS, a CpG site not methylated by HpaII
methylase, was quantitated and is expressed as a function of pixantrone
concentration.
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5GC methylation by HhaI methylase
enhances the generation of pixantrone–DNA adducts
Given the enhancement of pixantrone–DNA adducts at
CCm
5GG sequences, an alternative methylated sequence
was selected to further characterize the role of methylation
in the generation of pixantrone–DNA adducts. The 512bp
fragment was treated with HhaI methylase to speciﬁcally
methylate the internal cytosine of the target sequence
GCGC (denoted GCm
5GC). Following reaction of native
and HhaI-methylated DNA templates with formalde-
hyde and pixantrone, each sample was subjected to tran-
scription. A distinct increase in the intensity of
pixantrone-induced blockages was evident at GCm
5GC
sequences relative to unmethylated GCGC sites (Supple-
mentary Figure S1). Quantitation of these speciﬁc
blockages revealed a 2–3-fold increase in blockage
frequency at GCm
5GC sites (Supplementary Figure S2),
suggesting that methylation enhances pixantrone–DNA
adducts at these sites.
Localized Cm
5CGG methylation by MspI methylase does
not enhance the generation of pixantrone–DNA adducts
Having established that pixantrone–DNA adducts were
speciﬁcally enhanced at discrete CCm
5GG sequences, it
was of interest to probe the potential inﬂuence of
cytosine methylation at other neighbouring residues.
MspI methylase provided an ideal opportunity to investi-
gate this idea given its ability to speciﬁcally methylate the
external cytosine of CCGG (denoted Cm
5CGG). Both
native and MspI-methylated DNA templates were
prepared and reacted with formaldehyde and pixantrone
to generate drug–DNA adducts as originally described.
Drug-reacted templates were subjected to transcription
and yielded the transcription footprint illustrated in
Figure 2. Each of the pixantrone-induced blockages
located at the three CCGG sites (indicated by sites X, Y
and Z at the right of Figure 2B) were quantitated and are
expressed as a function of pixantrone concentration in
Figure 2C–E. Unlike HpaII methylation, Figure 2C–E
indicates that Cm
5CGG methylation had no eﬀect on
the generation of pixantrone–DNA adducts at these
sequences. The fraction of drug-induced transcriptional
blockages was quantitated at an unmethylated CpG site
(denoted CS at the right of Figure 2B). Figure 2F shows
that there was no diﬀerence in the generation of
pixantrone adducts at the unmethylated CpG site using
the native DNA template versus the MspI-methylated
template.
Formaldehyde-mediated alkylation of DNA by pixantrone
is enhanced in synthetic oligonucleotides containing
5-methyl-deoxycytosine
Chemically-modiﬁed oligonucleotides were subsequently
used to further evaluate the role of CpG methylation
in the DNA binding of formaldehyde-activated pixan-
trone. Both native and methylated 50-end labelled
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Figure 1. Continued.
Nucleic Acids Research, 2009,Vol.37, No. 19 6359oligonucleotides (25mMbp) were modiﬁed in a reaction
mixture containing 2mM formaldehyde and 0–50mM
pixantrone. Following an overnight incubation at 37 C,
drug-reacted oligonucleotides were resolved by electro-
phoresis on a denaturing polyacrylamide gel. The resulting
phosphorimage is presented in Figure 3A. The extent of
adduct-induced stabilization of each oligonucleotide
duplex, which is indicated by the uppermost band
(Figure 3A), was quantitated and is presented as a
function of pixantrone concentration in Figure 3B. The
generation of drug-stabilized duplexes was strongly depen-
dent on pixantrone concentration and there was a clear
2–5-fold enhancement in the alkylation of the fully
methylated oligonucleotide dsBE67 (Figure 3B, solid
line, open squares) relative to native duplex dsBE12
(Figure 3B, solid line, solid squares) throughout the
range of pixantrone concentrations tested.
Given the highly amenable nature of oligonucleotide
design, it was possible to construct two novel duplexes,
in which only one of the strands was methylated.
As substrates for alkylation by formaldehyde-activated
pixantrone, these hemi-methylated duplexes were not as
susceptible to adduct formation relative to the fully
methylated oligonucleotide dsBE67 (Figure 3B, solid
line, open squares), yet a moderate 1.25 to 2.5-fold
increase in pixantrone adduct formation was observed
within the hemi-methylated oligonucleotides dsBE17 and
dsBE26 (Figure 3B, dashed line, open circles and dashed
line, solid circles, respectively).
Mass spectrometric analysis of the covalent pixantrone–
dsBE12 and pixantrone–dsBE67 complexes
The binding of formaldehyde-activated pixantrone to
unmethylated duplex dsBE12 and fully methylated oligo-
nucleotide dsBE67 was subsequently analysed by mass
spectrometry. Reaction mixtures consisting of 100mM
pixantrone, 10mM formaldehyde and either dsBE12 or
dsBE67 (50mM) were constructed and incubated at 37 C
overnight. Drug–DNA complexes were subsequently pro-
cessed using electrophoresis and electroelution as
described in the ‘Materials and Methods’ section.
Finally, samples were subjected to mass spectrometric
analysis, which yielded the spectra presented in Figure 4.
Mass spectrometric analysis of the dsBE12-pixantrone
complex (Figure 4A) yielded a spectral pattern that was
fully consistent with the presence of dsBE12 (peak
12232Da), dsBE12-intercalated pixantrone (peak
12557Da) and the dsBE12-pixantrone covalent adduct
(peak 12569Da) and is summarized in Table 1.
Duplex dsBE67 was detected predominantly as a single
peak (Figure 4B) associated with a mass of 12291Da, a
value that compared favourably with the expected mass of
the duplex (Table 1). A second key peak was evident at
12615Da, a mass that is consistent with a single pixan-
trone molecule intercalated within the duplex (Table 1).
A third and very prominent peak was detected at
12627Da (Figure 4B), a mass which most likely reﬂects
the addition of a single methylene unit (mediated by
formaldehyde) to generate a single pixantrone–DNA
adduct (Table 1). The signal intensity of the covalent
drug–DNA complex at 12627Da (Figure 4B) compared
favourably to the peak intensity of the corresponding
covalent pixantrone–dsBE12 complex (12569Da peak
of Figure 4A), indicating that the binding of activated
pixantrone to the methylated duplex dsBE67 was
enhanced relative to the unmethylated duplex dsBE12.
A second cluster of peaks was also observed in
the 12940–70Da mass range of the spectra presented
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Figure 2. Drug-induced transcriptional blockages are not enhanced
at discrete MspI-methylated sequences. (A) A native 512bp DNA
fragment (25mMbp) was treated with pixantrone (0–10mM as indicated)
and 2mM formaldehyde for 4h. Drug-treated templates were
subsequently subjected to in vitro transcription, electrophoresis and
ﬁnally phosphorimaging. Controls are as described in Figure 1.
(B) The native 512bp fragment in (A) was substituted for an identical
fragment speciﬁcally methylated by MspI methylase at the external
cytosine of each CCGG recognition sequence. The MspI-methylated
fragment was then reacted with drug and subjected to transcription
as described in (A). Three MspI-methylated sites are indicated by X,
Y and Z at the right of the phosphorimage. CS denotes an
unmethylated CpG control site. The mole fraction of blockages at
MspI-methylated sites X, Y and Z and at an unmethylated control
site (CS), were quantitated and are expressed as a function of
pixantrone concentration in (C), (D), (E) and (F), respectively.
Unmethylated and methylated 512bp DNA substrates are denoted by
solid and open squares, respectively.
6360 Nucleic Acids Research, 2009,Vol.37, No. 19in Figure 4B. The ﬁrst and smallest of these signals at
12939Da (Figure 4B) is consistent with dsBE67 accom-
modating intercalation by two pixantrone molecules
(Table 1). The second and third peaks of this cluster
increased in multiples of 12–13Da (Figure 4B) and are
representative of the generation of one pixantrone–DNA
adduct (and one intercalated pixantrone) or two
pixantrone–DNA adducts (Table 1).
Pixantrone–DNA adduct stability is modestly inﬂuenced by
localized CpG methylation and only at select sequences
A marked and consistent enhancement in the generation
of covalent pixantrone–DNA adducts by CpG methyla-
tion prompted an investigation into the permanence of
these lesions at discretely methylated sites. The transcrip-
tion assay is ideal for the speciﬁc measurement of covalent
pixantrone–DNA adducts without interference by non-
covalent pixantrone–DNA interactions (7). Following
reaction with formaldehyde and pixantrone, either native
or methylated drug-reacted 512bp DNA templates were
subjected to transcriptional elongation for up to 4h.
The phosphorimage presented in Figure 5 shows the
eﬀect of HpaII methylation (CCm
5GG) on the decay of
transcriptional blockages with increasing elongation
times. The fraction of transcriptional blockages at individ-
ual sites X, Y and Z was quantitated for each entire lane of
Figure 5 and the persistence of these adducts, expressed as
a half-life at each site, is summarized in Table 2. An
assessment of the data presented in Table 2 suggests that
the stability of pixantrone–DNA adducts at CCGG sites is
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Figure 2. Continued.
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Figure 3. Pixantrone–DNA adduct induced stabilization of synthetic
oligonucleotides containing 5-methyl-deoxycytosine as assessed by a
gel shift assay. (A) Various oligonucleotides substrates (25mMbp)
including unmethylated dsBE12, hemi-methylated dsBE17 and dsBE26
and fully methylated dsBE67 were incubated with either 0, 1, 2.5, 5, 10,
25 or 50mM pixantrone (denoted by a solid triangle) and 2mM form-
aldehyde overnight at 37 C in PBS (pH 7.0). Drug-treated samples were
then subjected to denaturing PAGE and phosphorimaging. (B) The
relative amount of dsDNA represented in (A) was quantitated and is
expressed as a function of pixantrone concentration (dsBE12, solid line,
solid squares; dsBE67, solid line, open squares; dsBE26, dashed line,
solid circles; dsBE17, dashed line, open circles).
Nucleic Acids Research, 2009,Vol.37, No. 19 6361only modestly enhanced by methylation at the internal
cytosine residue of the sequence. Moreover, methylation
of the external cytosine of the same recognition sequence
(Cm
5CGG) by MspI methylase had no signiﬁcant
inﬂuence on the stability of pixantrone–DNA adducts
(Table 2).
A gel shift assay was subsequently employed to
independently assess the stability of pixantrone–DNA
adducts at CpG methylated sites. Both unmethylated
dsBE12 and fully methylated dsBE67 oligonucleotide
complexes were initially reacted with pixantrone and
formaldehyde, subsequently puriﬁed to remove unreacted
drug and the drug-oligonucleotide complex incubated
at 37 C for deﬁned time periods up to 180min. The
loss of pixantrone adducts from the oligonucleotide
duplexes with time was monitored using a gel shift assay
(Figure 6A). The fraction of duplex DNA remaining as
double-stranded in Figure 6A was quantitated and is
expressed as a function of time in Figure 6B. The dissoci-
ation of adducts from either unmethylated dsBE12 or
methylated dsBE67 was identical, with pixantrone–
DNA adducts in each duplex displaying half-lives of
 150min.
DNA modiﬁcation by cisplatin is unaﬀected by CpG
methylation at localized CCGG (CCm
5GG) sequences
In an eﬀort to further investigate the role of CpG
methylation in drug–DNA damage, the covalent binding
of cisplatin at HpaII-methylated CCGG (CCm
5GG) sites
was analysed by in vitro transcription. Cisplatin (0–1mM)
was incubated with either a native or HpaII-methylated
Figure 4. Mass spectrometric analysis of oligonucleotide duplexes dsBE12 and dsBE67. The oligonucleotide duplexes dsBE12 (A) and dsBE67
(B) were incubated with 10mM formaldehyde and 100mM pixantrone in PBS (pH7.0) at 37 C overnight. Drug–oligonucleotide complexes were
subsequently processed and subjected to mass spectrometry as described in the ‘Materials and Methods’ section. The spectra are expressed as a
function of absolute molecular mass (Da).
Table 1. The expected and observed masses for each major peak
depicted in Figure 4
Figure 4 Reaction
conditions
Products Expected
mass
Observed
mass
(Da) (Da)
A 10mM formaldehyde
+100mM
pixantrone
dsBE12 12232 12232
+(1 Pixint) 12557 12557
+(1 Pixadd) 12569 12569
B 10mM formaldehyde
+100mM
pixantrone
dsBE67 12288 12291
+(1 Pixint) 12613 12615
+(1 Pixadd) 12625 12627
+(2 Pixint) 12938 12939
+(1 Pixint)
+(1 Pixadd)
12950 12952
+(2 Pixadd) 12962 12964
The abbreviations Pixint and Pixadd denote the intercalated species of
pixantrone and the pixantrone–DNA adduct, respectively. The molecular
mass of pixantrone is 325Da.
6362 Nucleic Acids Research, 2009,Vol.37, No. 19DNA fragment (25mMbp) in 0.5 TE overnight at 37 C.
Each drug-reacted template was subsequently subjected to
in vitro transcription. The phosphorimage presented in
Figure 7 indicates that cisplatin induced a clear dose-
dependent decrease in full length transcript using both
native and CCm
5GG-DNA templates. A concurrent
increase in cisplatin-induced transcriptional blockages
was also clearly evident (Figure 7A and B). Most
importantly, a subset of these blockages occurred at
CCGG sites within both DNA templates (indicated by
X, Y and Z at the left of Figure 7A). Note that the
blockages selectively occurred at the CpC of doublets of
these sites (i.e. GpG dinucleotide sequence of the template
strand). The relative occupancy of drug at sites X, Y and Z
was quantitated as a fraction of each entire lane and is
presented as a function of cisplatin concentration in
Figure 7C–E. Clearly, the two curves of each graph repre-
sented in Figure 7 (unmethylated sites, solid squares;
methylated DNA, open squares) closely coincide with
each other, suggesting that the generation of cisplatin
DNA adducts at each site was unaﬀected at localized
IE51 5 3 0 6 0 9 0 1 2 0 1 8 0 A C 240 I E 5 15 30 60 90 120180240
Unmethylated Methylated
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Figure 5. Elongation of the transcription complex past pixantrone-
induced blockages at unmethylated CCGG and HpaII-methylated
(CCm
5GG) sites. (A) The 512bp fragment was initially reacted with
5mM pixantrone and 2mM formaldehyde for 4h. Following ethanol
precipitation, drug-reacted DNA was resuspended and transcription
initiated from the lac UV5 promoter. Subsequent elongation of the
initiated complex was allowed to proceed at 37 C for time periods
ranging from 5 to 240min. Controls are as stated in the legend of
Figure 1. (B) The native 512bp fragment in (A) was substituted for
an identical fragment speciﬁcally methylated by HpaII methylase at the
internal cytosine of each CCGG recognition sequence. The methylated
fragment was subsequently reacted with drug and subjected to tran-
scription as described in (A). CCGG recognition sites are indicated
by X, Y and Z at the right of the phosphorimage.
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Figure 6. The stability of pixantrone–DNA adducts located within
unmethylated and CpG methylated oligonucleotide duplexes. (A)[
32P]-
End labelled duplexes (25mMbp) dsBE12 (unmethylated) and dsBE67
(methylated) were initially reacted with 50mM pixantrone and 2mM
formaldehyde in PBS (pH 7.0) at 37 C overnight. Following the
removal of unreacted drug, the covalent drug–DNA complex was
incubated at 37 C for deﬁned time periods up to 180min (as indicated).
Samples were then subjected to a gel shift assay as described in the
‘Materials and Methods’ section. (B) The fraction of DNA remaining as
double stranded in (A) was quantitated and is expressed as a function of
time (dsBE12, solid squares; dsBE67 open squares). Error bars represent
the absolute maximum error of two independent experiments.
Table 2. The stability of covalent pixantrone-DNA adducts at
unmethylated CCGG sites versus HpaII-methylated (CCm
5GG) and
MspI-methylated (Cm
5CGG) sequences
Site
HpaII methylation MspI methylation
 Me +Me  Me +Me
X 29±4 53±10 42±9 34±7
Y 18±0.5 29±0.5 22±0.5 20±2
Z 18±1 22±1 20±1 21±3
The stated values are the half-lives (in minutes) of adducts at each site
and were determined by ﬁtting the data to an exponential decay
function (ﬁrst order). The error associated with each value is the
standard error of the ﬁt. ‘ Me’ and ‘+Me’ represent unmethylated
and methylated CCGG sites, respectively.
Nucleic Acids Research, 2009,Vol.37, No. 19 6363CCm
5GG sequences. The frequency of transcriptional
blockages at a non-CCGG binding site (denoted CS at
the left of Figure 7A) was also quantitated and is
displayed as a function of cisplatin concentration in
Figure 7F. This result suggests that there was no signiﬁ-
cant diﬀerence in the generation of cisplatin adducts using
the two diﬀerent DNA templates.
DNA alkylation by the formaldehyde-activated
anthracyclines doxorubicin and epirubicin is selectively
enhanced at HhaI-methylated (GCm
5GC) sites
The eﬀect of CpG methylation on the alkylation of DNA
by formaldehyde-activated doxorubicin was subsequently
investigated within the 512bp DNA fragment. Each
GCGC site within the 512bp fragment was speciﬁcally
methylated at the internal cytosine residue by HhaI
methylase (denoted GCm
5GC). Methylation at these
sites incorporates both the natural substrate of DNA
methylation in the CpG doublet and two contiguous
GpC dinucleotides, the favoured binding site of
formaldehyde-activated doxorubicin. Clearly, this unique
permutation of nucleotides provides an ideal experimental
opportunity to investigate the potential modulation of
doxorubicin–DNA damage by CpG methylation.
Following reaction with formaldehyde (1mM) and
doxorubicin (0–250nM), the native, unmethylated 512bp
DNA fragment was subjected to in vitro transcription
from the lac UV5 promoter. Transcription of the
template yields a pattern of blockages (Figure 8A) that
are consistent with a typical footprint induced by
formaldehyde-activated doxorubicin (7). Drug-reacted
templates bearing methylated GCm
5GC sequences gen-
erated an identical proﬁle of transcriptional blockages
(Figure 8B), however the intensity of blockages at each
GCm
5GC site (denoted by U, V and W at the right of
Figure 8B) is greater relative to the equivalent sites in
the native, unmethylated fragment (Figure 8A). The
extent of drug-induced blockages at sites U, V and W
were quantitated as a fraction of transcripts in each lane
and are represented as a function of doxorubicin con-
centration (Figure 8C–E). A clear 2–3-fold increase in
blockage intensity at each GCm
5GC site relative to the
corresponding unmethylated sequence is evident (Figure
8C–E). An unmethylated GpC site alkylated by
formaldehyde-activated doxorubicin (denoted CS at
the right of Figure 8B) was quantitated as a control
(Figure 8F) to demonstrate that there was no signiﬁcant
diﬀerence in doxorubicin–DNA adduct formation at
unmethylated GpC doublets using the two diﬀerent
DNA templates.
A similar enhancement in DNA alkylation was
also displayed by formaldehyde-activated epirubicin,
another GpC-speciﬁc alkylator, at HhaI-methylated sites
(Supplementary Figure S3). The CpG methylation-
mediated enhancement of drug-induced blockages at site
U was especially pronounced (by up to 9-fold), while the
increase at sites V and W were more modest (by 2–3-fold),
but still signiﬁcant (Supplementary Figure S4). Again,
an unmethylated GpC site was quantitated and
showed no signiﬁcant diﬀerence in its alkylation by
activated epirubicin on the two independent templates
(Supplementary Figure S4).
Pixantrone and doxorubicin-induced growth inhibition in
wildtype versus HCT116DKO cells
The growth inhibitory eﬀect of pixantrone on HCT116
wildtype and HCT116DKO cells is presented in
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Figure 7. The eﬀect of CpG methylation on cisplatin-induced
transcriptional blockages at neighbouring CpC sequences. Cisplatin
(0–1mM as indicated) was initially reacted with either (A)a n
unmethylated or (B) a HpaII-methylated 512bp DNA fragment
(25mMbp) overnight at 37 C. Drug-reacted templates were directly sub-
jected to transcription as described in the legend of Figure 1. Controls
are also as described in Figure 1. Three CCGG sites targeted by HpaII
methylase are indicated by X, Y and Z at the left of the
phosphorimage. CS denotes a non-CCGG site modiﬁed by cisplatin,
but not methylated by HpaII methylase. The mole fraction of drug-
induced blockages at native (solid squares) and methylated (open
squares) CCGG sites X, Y and Z were quantitated as a fraction of
each entire lane and are represented as a function of cisplatin concen-
tration in (C), (D) and (E), respectively. (F) The % transcriptional
blockage of the control site CS, a non-CCGG site modiﬁed by cisplatin
but not methylated by HpaII methylase, was quantitated and is
expressed as a function of cisplatin concentration.
6364 Nucleic Acids Research, 2009,Vol.37, No. 19Figure 9. The methylation depleted HCT116DKO
cells displayed a 12-fold resistance to pixantrone, and a
10-fold resistance to doxorubicin. In contrast, this cell
line was only  2-fold resistant to cisplatin treatment
compared to the wildtype HCT116 cells, and may be
accounted at least in part by the comparatively slow
growth rate of the HCT116DKO cells.
DISCUSSION
DNA methylation is a covalent epigenetic modiﬁcation of
the mammalian genome that can occur at each cytosine
residue of the CpG motif. The modiﬁcation assumes a
critical role in both the regulation of gene expression
and the development of cancer (8,12,23). In addition to
being the predominant substrate of DNA methylation (8),
the CpG doublet is also a target of numerous DNA
damaging agents, including formaldehyde-activated
pixantrone (7,9,24,25). Since the bulk of CpG dinucle-
otides are likely to be methylated in vivo (8,9,25–27), the
present study initially examined the eﬀect of localized
CpG methylation on the alkylation of DNA by
formaldehyde-activated pixantrone.
CpG methylation augments the generation of covalent
pixantrone–DNA adducts
Three independent techniques, which included an in vitro
transcription assay (Figure 1), an oligonucleotide band
shift assay (Figure 3) and mass spectrometric analysis
(Figure 4), all provided clear evidence that CpG methyla-
tion enhanced DNA alkylation by formaldehyde-activated
pixantrone. Pixantrone joins an expanding catalogue of
DNA-damaging agents that are susceptible to modulation
by CpG methylation. Covalent modiﬁcation of DNA by
the chemical carcinogen N-methyl-N-nitrosourea (28) and
UV-induced photoproducts (29,30) are both inhibited by
proximal CpG methylation, yet other agents including
the benzo[a]pyrene metabolite BPDE (24,31,32), aﬂatoxin
B1-8,9-epoxide (33) and the therapeutic agents mitomycin
C (9,21,34), esperamicins A1 and C (25) and
formaldehyde-activated mitoxantrone (35,36) are all
enhanced at methylated CpG dinucleotides. Given that
each of these latter DNA-interactive agents (excluding
the esperamicins A1 and C) alkylate DNA via the
guanine residue of CpG doublets and are enhanced by
methylation at the 50 neighbouring cytosine, it would be
appealing to establish if these compounds and
formaldehyde-activated pixantrone share a common
reaction mechanism in their alkylation of the methylated
CpG motif.
Modulation of DNA binding by CpG methylation is
not a general feature of all alkylators
Activated doxorubicin strongly favours DNA alkylation
at GpC steps (7,37–40), yet the intercalated species of the
drug and other closely-related anthracyclines prefer
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Figure 7. Continued.
Nucleic Acids Research, 2009,Vol.37, No. 19 6365binding at the isomeric CpG doublet (41,42). Merging the
two dinucleotide sequences together yields the triplet
GCG, a sequence which is represented in the HhaI
methylase recognition site GCGC. Strikingly, when the
central CpG step of this speciﬁc site was methylated by
HhaI methylase, DNA alkylation by formaldehyde-
activated doxorubicin was enhanced by 2 to 3-fold at
neighbouring GpC sites (Figure 8). In contrast, the
covalent binding of cisplatin at localized CCGG sequences
was unaﬀected by methylation at the neighbouring central
CpG step (Figure 7), suggesting that modulation of DNA
binding by methylation may not be a general feature of
adduct-forming agents. Rather, the structural feature that
seems to confer an enhancement by CpG methylation is a
ﬂat, polycyclic ring system which permits non-covalent
interactions within DNA. Thus, intercalation at
methylated CpG steps may be a prerequisite for enhance-
ment of covalent drug–DNA adducts.
A molecular rationale for the augmentation of pixantrone
and doxorubicin–DNA damage at methylated CpG sites
Two distinct chemical mechanisms are generally con-
sidered in an eﬀort to account for the enhancement of
drug-induced DNA alkylation by CpG methylation.
First, it has been suggested that cytosine methylation
may increase the chemical reactivity of the N2 exocyclic
amino group of guanine, through which mitomycin C,
formaldehyde-activated mitoxantrone, BPDE and
formaldehyde-activated pixantrone covalently bind to
DNA (7,31,34,36). The N2 amino function of guanine
may be made more nucleophilic by the neighbouring
methyl group of the 5-methylcytosine via an electron-
donating eﬀect (24,34,43). The credibility of this idea has
been challenged since the methyl group of cytosine extends
into the major groove of DNA, quite distal to the reactive
N2 amino centre of guanine within the minor groove
(31). Moreover, Chen et al. (33) established that CpG
methylation augments DNA alkylation by a range of
bulky carcinogens, which covalently bind through
guanine at a variety of reactive centres including N7 and
C8 positions of the base, not just the N2 centre. Such a
result cannot be attributed to an increase in the
nucleophilicity of a single reactive centre and suggests
that a broader, less speciﬁc mechanism may be responsible
for the enhancement of drug-induced DNA alkylation by
CpG methylation.
An alternative mechanism involves a shift in the
initial structural accessibility of the alkylator by CpG
methylation to a more favourable position for the gener-
ation of a covalent bond with DNA. It is well established
that CpG methylation induces numerous conformational
alterations in the local structure of duplex DNA that
include enhancing the transition of DNA from B to Z
forms, increasing helical pitch and unwinding and
inﬂuencing the formation of DNA cruciforms, a unique
DNA secondary structure (21,44–48). By coincidence,
Vargason et al. (49) characterized the eﬀect of CpG
methylation on the hexamer d(GGCGCC)2, a sequence
repeated twice within the 512bp fragment used in the
present study for in vitro transcription. Pixantrone–DNA
alkylation was enhanced at both of these sequences in
HhaI-methylated templates (Supplementary Figure S2).
CpG methylation in the context of the hexamer d(GGC
GCC)2 induces a conformational change in the duplex
that is representative of a transition state from B-DNA
to A-DNA (49). Features speciﬁc to this unique duplex,
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Figure 8. Multiple blocked transcripts induced by doxorubicin–DNA
adducts at discrete HhaI-methylated sequences. (A) An unmethylated
512bp DNA fragment (25mMbp) was initially incubated with 0–250nM
doxorubicin (as indicated) and 1mM formaldehyde for 4h at 37 C.
Each reaction was terminated by ethanol precipitation and drug-
reacted samples subsequently resuspended and subjected to transcrip-
tion as described in the legend of Figure 1. Controls are as described in
Figure 1. (B) The native 512bp DNA fragment in (A) was substituted
for an identical fragment speciﬁcally methylated by HhaI methylase at
the internal cytosine of each GCGC recognition sequence. The HhaI-
methylated fragment was subsequently reacted with drug and subjected
to transcription as described in (A). Three GCGC sites, targeted by
HhaI methylase, are indicated by U, V and W at the right of the
phosphorimage. CS represents an unmethylated GpC site alkylated
by formaldehyde-activated doxorubicin. The amount of RNA tran-
script at unmethylated (solid squares) and methylated (open squares)
U, V and W sites was quantitated and is expressed as a function of
doxorubicin concentration in (C), (D) and (E), respectively. (F) The
mole fraction of RNA transcript at control site CS, a GpC site not
methylated by HhaI methylase, was quantitated and is expressed as a
function of doxorubicin concentration.
6366 Nucleic Acids Research, 2009,Vol.37, No. 19such as an extended helical rise (49), may facilitate the
enhancement of pixantrone–DNA adducts observed at
these sequences.
The methyl moiety of 5-methylcytosine protrudes
sterically out into the hydrophilic major groove of duplex
DNA and imparts an element of hydrophobicity to its
proximal region (47) and this may be pertinent to DNA
alkylators that also interact with DNA via non-covalent
intercalation, a mode of binding that is distinct from their
capacity to covalently modify DNA. The benzo[a]pyrene
metabolite BPDE, 2,7-diaminomitosene (a primary
mitomycin C metabolite) and mitoxantrone are three
examples of agents that display both modes of DNA
binding in the appropriate environment. Interestingly,
the non-covalent intercalative binding of all three
are signiﬁcantly enhanced by methylated CpG DNA
(36,50,51), suggesting that methylation-enhanced drug–
DNA intercalation may be a precursor to increased
drug–DNA alkylation.
A further indication that localized CpG methylation
may enhance initial drug intercalation is provided by
in vitro transcription studies of the MspI-methylated
template (Figure 2). MspI methylation at the external
cytosine residues of CCGG sites failed to enhance
formaldehyde-activated pixantrone DNA alkylation
(Figure 2), indicating that the methyl substituents must
be positioned at the internal cytosine residues of the rec-
ognition motif to augment DNA alkylation. Presumably,
the internal CpG site of the recognition sequence CCGG
is also the site of initial intercalation of pixantrone.
Molecular modelling analysis of the mitoxantrone–
DNA intercalation complex has demonstrated that
CpG methylation essentially shifts the distribution of
intercalated drug from the major to the minor groove
(36). The methyl moiety of 5-methylcytosine may
achieve this shift in equilibrium by sterically protruding
out into the major groove, thereby impairing drug entry.
Once positioned within the minor groove of DNA, the
drug is ideally situated for covalent reaction with the
adjacent N2 amino group of guanine, the established
site of DNA alkylation by formaldehyde-activated
mitoxantrone (36). Given their strong structural similar-
ity, formaldehyde-mediated mitoxantrone, doxorubicin
and pixantrone–DNA alkylation are most likely to be
enhanced by CpG methylation via highly analogous
mechanisms.
The generation of CpG selective pixantrone–DNA adducts
may impair the activity of DNMTs, which speciﬁcally
target the doublet
A consistent feature of almost every tumour type is their
tendency to accommodate a large range of tumour sup-
pressor and cancer-related genes that are characteristically
silenced by CpG methylation in their promoter regions
(12,15). These cancer-speciﬁc methylation patterns must
be actively maintained between cell generations by
DNMTs for progenitor cells to retain their survival
advantage(15,52).Therapeuticallydisruptingthetransmis-
sion of cancer-associated methylation patterns enables
the reactivation of once-dormant tumour suppressor
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Figure 8. Continued.
Nucleic Acids Research, 2009,Vol.37, No. 19 6367genes (47). Moreover, the reversible nature of DNA
methylation suggests that this can be achieved without
altering the DNA sequence (53,54). A distinctive feature
of the methylation-enhanced generation of pixantrone–
DNA adducts is that hemi-methylation is suﬃcient to
induce a signiﬁcant 1.25–2.5-fold increase in DNA
alkylation by these lesions (Figure 3). Pixantrone–DNA
adduct formation at both unmethylated and hemi-
methylated CpG doublets has potential biological
implications, since these particular sequences are also
receptors of cellular DNMTs.
Historically, the inhibition of DNA methylation
and gene reactivation as therapeutic targets has been
achieved using the nucleoside analogues 5-aza-20-
deoxycytidine and 5-aza-cytidine (12,52,55,56). Nucleo-
sides such as these induce their cytotoxic properties by
poisoning DNMTs following their incorporation into
DNA (52,56). The development of nucleosides as thera-
peutic compounds has been impaired primarily by their
inherent toxicity, a characteristic commonly attributed
to their non-speciﬁc incorporation into DNA (52,55,56).
The deleterious nature of these compounds has placed
an emphasis on the development of non-nucleoside
inhibitors of DNMTs. A handful of such molecules have
recently been identiﬁed and described. Procainamide and
procaine are two small molecule 4-aminobenzoic acid
derivatives that inhibit DNMT activity, an outcome that
may be attributed to their strong binding to DNA rich in
the CpG motif (52,55,56). Both agents induce global and
localized CpG island-demethylation and re-expression
of the associated genes in a cellular environment (55,57)
and these eﬀects may contribute towards their growth
inhibitory properties. Similarly, formaldehyde-activated
mitoxantrone, a close structural analogue of pixantrone,
can also mediate localized demethylation of CpG islands
in several cancer-associated genes (58). A functional con-
sequence of this demethylation was the reactivation of the
associated gene.
The CpG speciﬁc alkylator BPDE provides a further
interesting example. It is well established that BPDE-
modiﬁed DNA is a poor substrate for methylation
catalysed by highly puriﬁed maintenance and de novo
DNA methylases and DNMTs in vitro (59–61), suggesting
that BPDE inhibits the activity of these enzymes. Within a
cellular environment, benzo[a]pyrene, the metabolic pre-
cursor of BPDE, has been reported to induce a signiﬁcant
decrease in global content of 5-methylcytosine (62,63).
More speciﬁcally, the carcinogen can induce hypometh-
ylation at localized genomic repeats (64) and elicit
changes in cellular gene expression in a time and dose-
dependent manner (65).
The CpG selective nature of formaldehyde-activated
pixantrone may help confer the drug with the properties
necessary for inhibiting DNMTs. Despite their obvious
diﬀerences, the common DNA-damaging attributes
shared by benzo[a]pyrene and formaldehyde-activated
pixantrone suggests that pixantrone may generate similar
cellular responses worthy of investigation. Clearly, they
include the potential reactivation of silenced cancer-
related genes by DNA demethylation and the inhibition
of DNMTs in vivo.
The enhancement of pixantrone–DNA and doxorubicin–
DNA lesions at methylated CpG doublets may confer
a selective toxicity in certain cancers
Endogenous levels of formaldehyde have previously
been shown to be suﬃcient for the formation of
doxorubicin–DNA adducts in MCF-7 cells (66). Since
many tumours have characteristically elevated formalde-
hyde levels (67,68) this provides an environment for the
formation of doxorubicin and pixantrone–DNA adducts.
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Figure 9. Representative growth inhibition curves of HCT116
(closed circles) and HCT116DKO (open circles) cells as determined
by an MTT assay after 72h treatment with doxorubicin (A), pixantrone
(B) or cisplatin (C). Error bars represent the standard deviation of four
replicates of a single typical experiment. The inset indicates the IC50
value (mM) of each drug and the error represents the standard deviation
of at least three independent experiments.
6368 Nucleic Acids Research, 2009,Vol.37, No. 19The biological signiﬁcance of the methylation-mediated
enhancement of pixantrone- and doxorubicin–DNA
lesions was addressed through the use of HCT116DKO
colon cancer cells vastly deﬁcient in genomic DNA
methylation (69). These cells, retaining just 5% of the
genomic DNA methylation content of their parental line
(69), were 12- and 10-fold more resistant to pixantrone-
and doxorubicin-induced growth inhibition, respectively
(Figure 9), suggesting higher levels of genomic CpG
methylation may be a determinant in the cytotoxicity of
these drugs. In contrast, cisplatin, a drug insensitive
to CpG methylation in vitro (Figure 7), induced only
a marginal 2-fold diﬀerence in growth inhibition
(Figure 9). The minor cisplatin-induced diﬀerential in
growth inhibition hints that the drug may not be sensitive
to the DNA methylation proﬁle of a given cell type,
consistent with in vitro data (Figure 7).
The use of the methylation-deﬁcient HCT116DKO cells
highlights that diﬀerential genomic CpG methylation
patterns may have signiﬁcant implications for pixantrone-
and doxorubicin-induced cell death. The challenge now is
to reﬁne this relationship and establish if a characteristic
pattern of CpG methylation, or ‘methylome’, engenders a
cancer with a particular susceptibility to these agents.
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